Addiction of primary cutaneous γδ T cell lymphomas to JAK/STAT signaling

Yue Zhang^{1

2}, Julia A Yescas¹, Kristy Tefft¹, Spencer Ng^{1

3}, Kevin Qiu¹, Erica B Wang⁴, Shifa Akhtar⁵, Addie Walker⁶, Macartney Welborn⁶, Martin Zaiac⁷, Joan Guitart¹, Aamir M Qureshi⁸, Youn H Kim⁴, Michael S Khodadoust^{4

9}, Naiem T Issa⁵, Jaehyuk Choi¹

Affiliations

¹ Department of Dermatology, Northwestern University, Chicago, Illinois, USA.
² Department of Dermatology, Indiana University, Indianapolis, Indiana, USA.
³ Division of Dermatology, Department of Medicine, and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
⁴ Department of Dermatology, Stanford University, Palo Alto, California, USA.
⁵ Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA.
⁶ Department of Dermatology, University of Florida, Gainesville, Florida, USA.
⁷ Department of Dermatology, Florida International University, Miami, Florida, USA.
⁸ Incyte Corporation, Wilmington, Delaware, USA.
⁹ Division of Oncology, Stanford Medicine, Stanford, California, USA.

Yue Zhang et al. J Clin Invest. 2025.

. 2025 Apr 15;135(8):e180417.

doi: 10.1172/JCI180417.

¹ Department of Dermatology, Northwestern University, Chicago, Illinois, USA.
² Department of Dermatology, Indiana University, Indianapolis, Indiana, USA.
³ Division of Dermatology, Department of Medicine, and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
⁴ Department of Dermatology, Stanford University, Palo Alto, California, USA.
⁵ Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA.
⁶ Department of Dermatology, University of Florida, Gainesville, Florida, USA.
⁷ Department of Dermatology, Florida International University, Miami, Florida, USA.
⁸ Incyte Corporation, Wilmington, Delaware, USA.
⁹ Division of Oncology, Stanford Medicine, Stanford, California, USA.

No abstract available

Keywords: Bioinformatics; Cancer; Dermatology; Oncology; Skin cancer.

Figures

1. Guitart J, et al. Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012;36(11):1656–1665. doi: 10.1097/PAS.0b013e31826a5038. - DOI - PubMed
1. Daniels J, et al. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nat Commun. 2020;11(1):1806. doi: 10.1038/s41467-020-15572-7. - DOI - PMC - PubMed
1. Horwitz SM, et al. A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood. 2019;134(supplement_1):466. doi: 10.1182/blood-2019-123986. - DOI
1. Moskowitz AJ, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828–2837. doi: 10.1182/blood.2021013379. - DOI - PMC - PubMed
1. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703. doi: 10.1056/NEJMoa1210093. - DOI - PMC - PubMed